Tuesday, October 13, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 15, 2026

Procter & Gamble (PG) Stock After Recent Pullback Is The Current Price Tag Justified

View original at finance.yahoo.com
Procter & Gamble (PG) Stock After Recent Pullback Is The Current Price Tag Justified Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Procter & Gamble is a large consumer staples stock that many investors watch closely when reassessing defensive holdings and income-focused positions

    60% confidence

  • The DCF model uses analyst-provided free cash flow estimates for the next few years, then extrapolates beyond that horizon

    60% confidence

  • Procter & Gamble's free cash flow is projected to reach approximately $21.3 billion by 2035 under the DCF model's assumptions

    60% confidence

  • The estimated intrinsic value of Procter & Gamble is approximately $186.75 per share based on discounted cash flow modeling

    60% confidence

  • Procter & Gamble scores 3 out of 6 on Simply Wall St's 6-point valuation checklist

    60% confidence

  • The DCF model output implies Procter & Gamble stock is 19.9% undervalued relative to its current share price of approximately $149.61

    60% confidence

Data points we hold from this source

Procter & Gamble · stock price149.61 USD
Procter & Gamble · margin2.1 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com
Procter & Gamble (PG) Stock After Recent Pullback Is The Current Price Tag Justified — Source | Via News | Via News